The pharmaceutical consulting industry in Europe plays a vital role in supporting companies as they navigate the complicated drug development process. This sector includes consulting firms, research organizations, and technology developers that provide services ranging from regulatory compliance and market access to clinical development strategies. With a growing emphasis on personalized medicine and digital health solutions, the industry is adapting to leverage advancements in biotechnology. As pressure on healthcare systems increases, pharmaceutical consulting firms are positioned to offer innovative approaches that meet both regulatory demands and patient needs, driving efficiency and better health outcomes.


The list of top pharmaceutical consulting investors showcases a mix of various investor types including corporate entities, venture capital firms, and private equity groups that shape the investment landscape. These investors are primarily headquartered in key European cities such as Basel, Paris, and Amsterdam, with firm sizes ranging from small teams to large corporations. Established from 1953 to 2015, they have collectively executed an impressive number of deals in 2024, highlighting an active investment environment eager to support innovation in pharmaceuticals.


Top 17 Pharmaceutical Consulting Investors in Europe


1. Novo Holdings

  • Website: novoholdings.dk
  • Type: Venture Capital
  • Headquarters: Hellerup, Denmark
  • Founded year: 1999
  • Headcount: 51-200
  • Number of deals in 2024: 45
  • LinkedIn: novo-a-s

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages the assets of the Novo Nordisk Foundation and focuses on investing in life science companies at various stages of development. Novo Holdings provides capital and strategic support to enhance healthcare solutions. Notably, they have made significant investments in the pharmaceutical consulting context, including the acquisition of Catalent Pharma Solutions for $16.5 billion, which is a major player in contract manufacturing for the pharmaceutical industry. Additionally, their acquisition of Medical Knowledge Group suggests a commitment to supporting consulting services that can aid pharmaceutical companies in their operations. These transactions highlight Novo Holdings' active role in the pharmaceutical sector, making it a relevant investor in the pharmaceutical consulting industry.


2. Bpifrance French Tech Accélération


Bpifrance French Tech Accélération is a venture capital investor based in Paris, Île-De-France, France, founded in 2015. As a public entity and financial institution, Bpifrance supports entrepreneurs and businesses in France and internationally through various services, including direct funding, export credit insurance, and private equity investments. The institution aims to foster entrepreneurship and innovation, helping businesses navigate growth and international expansion. Notably, Bpifrance has been involved in several transactions relevant to the pharmaceutical sector, such as a venture round for NovAliX, which focuses on drug development, and a seed funding round for Vaxxel, a startup developing an intranasal vaccine candidate. Furthermore, Bpifrance's partnership in the acquisition of Healthy Group highlights its commitment to supporting growth and innovation in the healthcare industry.


3. European Innovation Council (EIC)


The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, the EIC offers various funding programs, including the EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale their technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, the EIC has been involved in several transactions relevant to the pharmaceutical consulting industry, such as providing grants to companies like Precisionlife, which raised $2,607,967 in February 2025, and Qubit Pharmaceuticals, which received multiple grants totaling over $3 million. These transactions highlight the EIC's role in supporting innovative pharmaceutical ventures, making it a significant player in the consulting landscape for this industry.


4. Accenture

  • Website: accenture.com
  • Type: Corporate
  • Headquarters: Dublin, Dublin, Ireland
  • Founded year: 2001
  • Headcount: 10001+
  • Number of deals in 2024: 51
  • LinkedIn: accenture

Accenture is a global consulting firm based in Dublin, Ireland, specializing in information technology and management consulting services. Founded in 2001, the firm has grown to employ over 10,000 professionals and operates across various industries, including healthcare and life sciences. In 2023, Accenture acquired Bionest Partners, a consultancy that enhances its capabilities in the life sciences sector, particularly in biopharma consulting. Additionally, the acquisition of Nautilus Consulting, a leading digital healthcare consultancy in the U.K., further strengthens Accenture's position in the healthcare consulting market. These strategic moves reflect Accenture's focus on innovation and digital transformation in the pharmaceutical sector, aligning with its broader mission to help businesses improve efficiency and navigate complex challenges.


5. Sofinnova Partners


Sofinnova Partners is a venture capital firm based in Paris, Île-De-France, France, founded in 1972. The firm specializes in life sciences investments, focusing on innovative healthcare startups through funding and strategic guidance. They have a diverse portfolio that includes significant investments in the biopharma sector. Notable transactions include a $138 million Series C financing round for Amolyt Pharma, aimed at advancing therapeutics for rare endocrine disorders, and a $143 million Series B financing for CinCor Pharma, which is developing a treatment for hypertension and related conditions. Additionally, they participated in a $35 million Series A round for Delinia, further showcasing their commitment to supporting pharmaceutical innovations. Their operations are geared towards fostering scientific advancements and sustainability in healthcare, making them a relevant player in the pharmaceutical consulting landscape.


6. Novartis Venture Fund

  • Website: nvfund.com
  • Type: Venture Capital
  • Headquarters: Basel, Basel, Switzerland
  • Founded year: 1996
  • Headcount: 11-50
  • Number of deals in 2024: 10

The Novartis Venture Fund, founded in 1996 and based in Basel, Switzerland, is a venture capital firm that specializes in life sciences investments. The firm focuses on providing funding and support to innovative biotechnology and biopharmaceutical companies, helping them develop novel therapeutics and address unmet patient needs. In recent years, the fund has participated in several notable transactions, including a $53 million Series B funding round for Amphista Therapeutics, which was co-led by other prominent investors, and a Series B financing for Kedalion Therapeutics, where Novartis had an exclusive option to acquire the company and its AcuStream technology. These transactions highlight the fund's active role in supporting companies that are at the forefront of pharmaceutical innovation, making it a significant player in the life sciences sector.


7. HBM Healthcare Investments AG


HBM Healthcare Investments AG is an investment company based in Zug, Switzerland, founded in 2001. It specializes in the healthcare sector, managing a diversified portfolio that includes investments in human medicine, biotechnology, medical technology, and diagnostics. The firm actively seeks growth opportunities in the rapidly evolving healthcare market. Notable transactions include their investment in SAI Life Sciences, which raised $2.7 million in 2019, and multiple funding rounds for Swixx Biopharma, where they co-invested alongside Mérieux Equity Partners, contributing an additional €5 million to support the company's growth. These transactions highlight HBM's commitment to advancing healthcare solutions and their strategic involvement in companies that may benefit from consulting services in the pharmaceutical sector.


8. Forbion

  • Website: forbion.com
  • Type: Venture Capital
  • Headquarters: Naarden, North Holland, Netherlands
  • Founded year: 2006
  • Headcount: 11-50
  • Number of deals in 2024: 23
  • LinkedIn: forbion-capital-partners

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, Netherlands. The firm specializes in the life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative therapies and technologies aimed at improving patient outcomes. Notable transactions include leading a $28M seed financing round for Orbis Medicines, which focuses on developing macrocycle drugs, and co-leading a $53M Series B funding for Amphista Therapeutics, which is involved in innovative therapeutic solutions. These investments highlight Forbion's commitment to advancing the pharmaceutical industry and addressing critical medical needs.


9. Abingworth

  • Website: abingworth.com
  • Type: Venture Capital
  • Headquarters: London, England, United Kingdom (UK)
  • Founded year: 1973
  • Headcount: 11-50
  • Number of deals in 2024: 6
  • LinkedIn: abingworth

Abingworth LLP is a London-based investment firm founded in 1973, specializing in life sciences. The firm focuses on providing capital and strategic support to biopharmaceutical companies, helping them develop innovative treatments. Abingworth's clients are primarily businesses in the biotechnology sector seeking funding for clinical development. They employ a multi-pronged investment strategy that includes venture investments and clinical co-development financing. Notable transactions include funding for Avillion, which focuses on clinical co-development of therapeutics, and SFJ Pharmaceuticals, which raised $45 million in a Series A round. Additionally, Abingworth has invested in Launch Therapeutics and participated in significant funding rounds for established companies like Gilead Sciences and Alnylam Pharmaceuticals, further demonstrating their active role in the pharmaceutical consulting landscape.


10. Novartis

  • Website: novartis.com
  • Type: Corporate
  • Headquarters: Basel, Basel, Switzerland
  • Founded year: 1996
  • Headcount: 10001+
  • Number of deals in 2024: 7
  • LinkedIn: novartis

Novartis AG, based in Basel, Switzerland, is a leading pharmaceutical company founded in 1996. With a workforce of over 10,000 employees, Novartis focuses on developing and manufacturing innovative medicines that address serious diseases across various therapeutic areas. The company emphasizes research and development to improve patient outcomes globally. Notable transactions include the acquisition of Endocyte for $2.1 billion, which enhances their radioligand therapy pipeline for prostate cancer, and the acquisition of AveXis for $8.7 billion, which strengthens their position in gene therapy. In 2024, Novartis announced the acquisition of Calypso Biotech for $250 million, further expanding their portfolio in autoimmune treatments. These strategic investments highlight Novartis's commitment to advancing healthcare solutions and their potential relevance in the pharmaceutical consulting sector.


11. European Investment Bank (EIB)


The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In the pharmaceutical consulting context, the EIB has been involved in several notable transactions, such as providing €15 million in funding to IRBM SpA to expand its research into coronavirus and other infectious diseases, supported by the EU’s InnovFin programme. Additionally, the EIB has participated in debt financing for Evotec, a prominent player in the pharmaceutical industry, raising substantial amounts in post-IPO debt. These transactions highlight the EIB's commitment to fostering innovation and growth in the pharmaceutical sector, making it a relevant investor in this field.


12. Life Sciences Partners (LSP)

  • Website: lspvc.com
  • Type: Venture Capital
  • Headquarters: Amsterdam, North Holland, Netherlands
  • Founded year: 1987
  • Headcount: 11-50
  • Number of deals in 2024: 15
  • LinkedIn: lsp-bioventures

Life Sciences Partners (LSP) is an investment firm based in Amsterdam, Netherlands, founded in 1987. The firm specializes in private equity investments within the healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, aiming to foster advancements that address unmet medical needs. Notable transactions include multiple funding rounds for Amolyt Pharma, which raised significant capital across Series A, B, and C rounds to advance its pipeline of therapeutics for rare endocrine disorders. Additionally, LSP's involvement with KuDOS Pharmaceuticals and Hyperion Therapeutics highlights their commitment to supporting companies that are at the forefront of pharmaceutical innovation. By providing capital and strategic support, LSP plays a crucial role in the healthcare ecosystem, making them a relevant player in the pharmaceutical consulting space.


13. Almi

  • Website: almi.se
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 201-500
  • Number of deals in 2024: 7
  • LinkedIn: almi-ab

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden. Almi aims to enhance the growth and competitiveness of these businesses by offering tailored financial solutions and guidance. Notably, Almi has been involved in several transactions within the pharmaceutical sector, including investments in Captario, which focuses on optimizing drug development cycles, and Phenaros Pharmaceuticals, which is in the pre-seed stage of development. These investments highlight Almi's engagement with companies that contribute to the pharmaceutical consulting landscape, showcasing their commitment to supporting innovation in this industry.


14. Scottish Enterprise


Scottish Enterprise is a public entity established in 1991, dedicated to fostering economic development in Scotland. With a workforce of 1001-5000 employees, it provides a variety of services, including funding, business development advice, and support for innovation and exports. The organization primarily serves businesses looking to enhance their operations and growth potential. Notably, Scottish Enterprise has been involved in several transactions within the pharmaceutical sector, such as a $7.5 million investment in Amphista Therapeutics during their Series A round in April 2020 and a $5.57 million investment in Cumulus Oncology during their Seed Round in February 2022. These transactions highlight Scottish Enterprise's active role in supporting pharmaceutical companies, thereby contributing to the advancement of the industry in Scotland.


15. Nextech Invest


Nextech Invest is a Zurich-based venture capital firm founded in 1998, specializing in biotechnology with a strong emphasis on cancer therapeutics. The firm invests in promising drug discovery companies and offers strategic support to help these firms navigate the complexities of drug development. Their portfolio includes significant investments in companies like MolecularMD, which raised $6 million in Series B funding, and Arrakis Therapeutics, which secured $75 million in Series B financing. Additionally, they participated in a $56 million Series B round for Jounce Therapeutics, focusing on monoclonal antibody cancer immunotherapy programs. Most recently, Nextech Invest invested $67 million in Delphia Therapeutics in a Series A round in 2024. These transactions underscore their commitment to advancing pharmaceutical innovations and providing operational guidance to their portfolio companies.


16. Agoranov

  • Website: agoranov.com
  • Type: Corporate
  • Headquarters: Paris, Île-De-France, France
  • Founded year: 2000
  • Headcount: 11-50
  • Number of deals in 2024: 42
  • LinkedIn: agoranov

Agoranov is a corporate startup incubator based in Paris, Île-De-France, founded in 2000. They specialize in supporting technology and science startups through personalized assistance, fully equipped facilities, and acceleration programs. With a focus on early-stage startups, Agoranov has been involved in various funding transactions, including notable ones in the pharmaceutical context. For instance, they provided non-equity assistance to Theremia, which raised $3,170,000 in 2024, and to One Biosciences, which also received non-equity assistance in 2020. These transactions suggest that Agoranov is actively engaged in nurturing companies that may operate within the pharmaceutical sector, thereby enhancing their relevance to pharmaceutical consulting.


17. Andera Partners

  • Website: anderapartners.com
  • Type: Private Equity
  • Headquarters: Paris, Île-De-France, France
  • Founded year: 1953
  • Headcount: 51-200
  • Number of deals in 2024: 10
  • LinkedIn: anderapartners

Andera Partners is a private equity firm based in Paris, Île-De-France, France, founded in 1953. The firm specializes in investment management and focuses on providing financial support and strategic guidance to companies across various sectors, including life sciences and infrastructure. In recent years, Andera Partners has been actively involved in the life sciences sector, participating in significant funding rounds for biotech firms. Notably, they invested in ReViral, which raised substantial funds in Series A, B, and C financing rounds to support the development of its antiviral therapies. Additionally, they have shown interest in Amolyt Pharma, which is advancing therapeutics for rare endocrine disorders. These transactions highlight Andera Partners' commitment to supporting innovation and growth in the pharmaceutical and biotech industries.



Pharmaceutical Consulting Insights: Key Investors in Europe


InvestorHeadquarterSizeFoundedDeals 2024
Novo HoldingsHellerup, Denmark51-200199945
Bpifrance French Tech AccélérationParis, Île-De-France, France1-102015198
European Innovation Council (EIC)Brussels, Brussels, Belgium201-500195857
AccentureDublin, Dublin, Ireland10001+200151
Sofinnova PartnersParis, Île-De-France, France51-200197225
Novartis Venture FundBasel, Basel, Switzerland11-50199610
HBM Healthcare Investments AGZug, Zug, Switzerland1001-500020018
ForbionNaarden, North Holland, Netherlands11-50200623
AbingworthLondon, England, United Kingdom (UK)11-5019736
NovartisBasel, Basel, Switzerland10001+19967
European Investment Bank (EIB)Luxembourg1001-5000195899
Life Sciences Partners (LSP)Amsterdam, North Holland, Netherlands11-50198715
AlmiStockholm, Stockholm, Sweden201-50019947
Scottish EnterpriseGlasgow, Scotland, United Kingdom (UK)1001-5000199155
Nextech InvestZurich, Zurich, Switzerland11-50199813
AgoranovParis, Île-De-France, France11-50200042
Andera PartnersParis, Île-De-France, France51-200195310


Want to find more investors focusing on the pharmaceutical consulting industry?

If you want to find more investors that are active in the pharmaceutical consultingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!